Cargando…

[(99m)Tc]Tc-iFAP/SPECT Tumor Stroma Imaging: Acquisition and Analysis of Clinical Images in Six Different Cancer Entities

Fibroblast activation protein (FAP) is highly expressed on the cancer-associated fibroblasts (CAF) of the tumor stroma. Recently, we reported the preclinical evaluation and clinical biokinetics of a novel (99m)Tc-labeled FAP inhibitor radioligand ([(99m)Tc]Tc-iFAP). This research aimed to evaluate [...

Descripción completa

Detalles Bibliográficos
Autores principales: Vallejo-Armenta, Paola, Ferro-Flores, Guillermina, Santos-Cuevas, Clara, García-Pérez, Francisco Osvaldo, Casanova-Triviño, Pamela, Sandoval-Bonilla, Bayron, Ocampo-García, Blanca, Azorín-Vega, Erika, Luna-Gutiérrez, Myrna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9230816/
https://www.ncbi.nlm.nih.gov/pubmed/35745648
http://dx.doi.org/10.3390/ph15060729
Descripción
Sumario:Fibroblast activation protein (FAP) is highly expressed on the cancer-associated fibroblasts (CAF) of the tumor stroma. Recently, we reported the preclinical evaluation and clinical biokinetics of a novel (99m)Tc-labeled FAP inhibitor radioligand ([(99m)Tc]Tc-iFAP). This research aimed to evaluate [(99m)Tc]Tc-iFAP for the tumor stroma imaging of six different cancerous entities and analyze them from the perspective of stromal heterogeneity. [(99m)Tc]Tc-iFAP was prepared from freeze-dried kits with a radiochemical purity of 98 ± 1%. The study included thirty-two patients diagnosed with glioma (n = 5); adrenal cortex neuroendocrine tumor (n = 1); and breast (n = 21), lung (n = 2), colorectal (n = 1) and cervical (n = 3) cancer. Patients with glioma had been evaluated with a previous cranial MRI scan and the rest of the patients had been involved in a [(18)F]FDG PET/CT study. All oncological diagnoses were corroborated histopathologically. The patients underwent SPECT/CT brain imaging (glioma) or thoracoabdominal imaging 1 h after [(99m)Tc]Tc-iFAP administration (i.v., 735 ± 63 MBq). The total lesions (n = 111) were divided into three categories: primary tumors (PT), lymph node metastases (LNm), and distant metastases (Dm). [(99m)Tc]Tc-iFAP brain imaging was positive in four high-grade WHO III–IV gliomas and negative in one treatment-naive low-grade glioma. Both [(99m)Tc]Tc-iFAP and [(18)F]FDG detected 26 (100%) PT, although the number of positive LNm and Dm was significantly higher with [(18)F]FDG [82 (96%)], in comparison to [(99m)Tc]Tc-iFAP imaging (35 (41%)). Peritoneal carcinomatosis lesions in a patient with recurrent colorectal cancer were only visualized with [(99m)Tc]Tc-iFAP. In patients with breast cancer, a significant positive correlation was demonstrated among [(99m)Tc]Tc-iFAP uptake values (Bq/cm(3)) of PT and the molecular subtype, being higher for subtypes HER2+ and Luminal B HER2-enriched. Four different CAF subpopulations have previously been described for LNm of breast cancer (from CAF-S1 to CAF-S4). The only subpopulation that expresses FAP is CAF-S1, which is preferentially detected in aggressive subtypes (HER2 and triple-negative), confirming that FAP+ is a marker for poor disease prognosis. The results of this pilot clinical research show that [(99m)Tc]Tc-iFAP SPECT imaging is a promising tool in the prognostic assessment of some solid tumors, particularly breast cancer.